Archer Materials Limited ( (AU:AXE) ) just unveiled an announcement.
Archer Materials Limited has made significant progress in the development of its Biochip technology, which is designed for at-home testing of chronic kidney disease by detecting potassium levels. The company has successfully reduced the variability in test results on its graphene field effect transistors, allowing it to move forward with testing human blood samples and integrating the Biochip into a prototype cartridge system. Archer plans to engage with regulatory bodies in the second half of 2025 and aims to commence clinical trials in 2026, marking a crucial step towards bringing the Biochip to market.
More about Archer Materials Limited
Archer Materials Limited is a semiconductor company that is advancing the quantum technology and medical diagnostics industries.
YTD Price Performance: -39.79%
Average Trading Volume: 197,309
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $54.4M
See more insights into AXE stock on TipRanks’ Stock Analysis page.